O-phenyl N-(3-methoxyphenyl)carbamate | 50699-51-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-phenyl N-(3-methoxyphenyl)carbamate
• 英文别名: phenyl N-(3-methoxyphenyl)carbamate；phenyl 3-methoxyphenylcarbamate；phenyl N-(3-methoxylphenyl) carbamate；phenyl N-(3-methoxyphenyl)-carbamate；Phenyl N-(M-anisyl)carbamate
• CAS: 50699-51-9
• 化学式: C₁₄H₁₃NO₃
• mdl: MFCD00025763
• 分子量: 243.262
• InChiKey: WVMWKYUMMAHSGU-UHFFFAOYSA-N

物化性质

• 沸点：
  351.8±34.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  O-phenyl N-(3-methoxyphenyl)carbamate 在 对甲苯磺酸 、 三乙胺 、 对苯醌 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 5.33h， 生成 7-methoxy-3-phenethylquinazoline-2,4(1H,3H)-dione
  参考文献：
  名称：

  Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer

  摘要：

  We designed and synthesized quinazolin-2,4-dione-based hydroxamic acids to serve as selective competitive inhibitors of histone deacetylase-6 (HDAC6). The most potent and selective compound, 3d (IC50, 4 nM, HDAC6; IC50 > 10 mu M, HDAC1), substantially increased acetylation of alpha-tubulin instead of histones in the lung cancer cell line, LL2. Paclitaxel in combination with 3d had a synergistic anticancer effect on reduction of programmed death-ligand 1 expression in LL/2 cells. When given orally, 3d was mainly found to locate in the liver and lungs, at a concentration 18- to 70-fold greater, respectively, than in plasma. As an orally active HDAC6 inhibitor, 3d (20 mg/kg) potentiated paclitaxel antitumor activity (percentage tumor growth inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.

  DOI：

  10.1021/acs.jmedchem.8b01590
• 作为产物：
  描述：

  phenyl (2,4,6-trinitrophenyl) carbonate 、 间氨基苯甲醚 在 potassium chloride 作用下， 以 乙醇 、 水 为溶剂， 生成 O-phenyl N-(3-methoxyphenyl)carbamate
  参考文献：
  名称：

  碳酸二芳基酯的协同氨解：亲核试剂，非离去基团和亲核试剂的碱性的动力学敏感性

  摘要：

  4-甲基苯基，苯基和4-氯苯基-2,4,6-三硝基苯碳酸酯（的反应的动力学1，2，和3，分别地）与一系列苯胺和仲脂环族（SA）的胺已经进行了用分光光度法在44重量％的乙醇-水，在25.0℃下，离子强度0.2 M的布朗斯台德图（统计学校正）为碳酸盐的反应中1 - 3与苯胺和SA胺是线性的与斜率（β ñ在的范围内）分别归因于协调机制，分别为0.69–0.78和0.45–0.48。对于log k N对非离开的碱性（βNLG）和离开（β LG）基团进行了讨论。苯胺比等压SA胺更具反应性，这可能是由于后者提供的更大的位阻。©2012 Wiley Periodicals，Inc.国际化学杂志Kinet 44：604–611，2012

  DOI：

  10.1002/kin.20700

文献信息

• 9-aminoacridine derivatives and process for the preparation thereof
  申请人：Samjin Pharmaceutical Co., Ltd.

  公开号：US20020111491A1

  公开（公告）日：2002-08-15

  The present invention relates to new 9-aminoacridine derivatives of general formula (I), wherein A is hydrogen or (II) (wherein X is oxygen or sulfur, R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, nitro, amino, hydroxy, C 1 -C 4 lower alkylhydroxy, C 1 -C 4 lower alkylamino, C 1 -C 8 alkyl, C 1 -C 4 lower alkoxy or C 1 -C 4 lower alkyloxycarbonyl and m and n are independently an integer of 0, 1 or 2), R 6 , R 7 , R 8 and R 9 are independently C 1 -C 8 alkyl or C 1 -C 4 lower alkoxy, and Y is hydrogen, amino, -N═CHR′(wherein R′ is hydrogen, benzyl, C 1 -C 8 alkyl or C 1 -C 6 lower alkylamino), (III) (wherein R″ is hydrogen, benzyl, C 1 -C 8 alkyl or C 1 -C 6 lower alkylamino, and R′″ is hydrogen, benzyl, C 1 -C 8 alkyl or amino protecting group) or (IV) (wherein, X is as defined above, R 1 ′, R 2 ′, R 3 ′, R 4 ′ and R 5 ′ are independently hydrogen, halogen, nitro, amino, hydroxy, C 1 -C 4 lower alkylhydroxy, C 1 -C 4 lower alkylamino, C 1 -C 8 alkyl, C 1 -C 4 lower alkoxy or C 1 -C 4 lower alkylcarboxy, and q and r are independently an integer of 0, 1 or 2) or its pharmaceutically acceptable salt, and process for the preparation thereof.

  本发明涉及通式（I）的新9-氨基蒽衍生物，其中A为氢或（II）（其中X为氧或硫，R1、R2、R3、R4和R5独立地为氢、卤素、硝基、氨基、羟基、C1-C4较低烷基羟基、C1-C4较低烷基氨基、C1-C8烷基、C1-C4较低烷氧基或C1-C4较低烷氧羰基，m和n独立地为0、1或2的整数），R6、R7、R8和R9独立地为C1-C8烷基或C1-C4较低烷氧基，Y为氢、氨基、-N═CHR′（其中R′为氢、苄基、C1-C8烷基或C1-C6较低烷基氨基）、（III）（其中R″为氢、苄基、C1-C8烷基或C1-C6较低烷基氨基，R′″为氢、苄基、C1-C8烷基或氨基保护基）或（IV）（其中，X如上定义，R1′、R2′、R3′、R4′和R5′独立地为氢、卤素、硝基、氨基、羟基、C1-C4较低烷基羟基、C1-C4较低烷基氨基、C1-C8烷基、C1-C4较低烷氧基或C1-C4较低烷基羧基，q和r独立地为0、1或2）或其药学上可接受的盐，以及其制备方法。
• Anilinolysis of reactive aryl 2,4-dinitrophenyl carbonates: Kinetics and mechanism
  作者：Enrique A. Castro、Claudia Domecq、José G. Santos

  DOI：10.1002/kin.20544

  日期：2011.4

  at constant pH are linear, with slopes kN. The Brønsted plots (log kN vs. anilinium pKa) for the anilinolysis of 1–3 are linear, with slope (β) values of 0.52, 0.61, and 0.63, respectively. The values of these slopes and other considerations suggest that these reactions are ruled by a concerted mechanism. For these reactions, the kN values follow the reactivity sequence: 3 > 2 > 1. Namely, the reactivity

  一系列苯胺与碳酸2,4-二硝基苯基（1），4-硝基苯基2,4-二硝基苯基（2）和双（2,4-二硝基苯基）（3）碳酸酯的反应在在25.0±0.1°C时，乙醇-水为44 wt％，离子强度为0.2M。在胺下，获得了过量的拟一级反应速率系数（k obs）。的曲线ķ OBS针对在恒定pH游离胺的浓度是线性的，与斜坡ķ Ñ。苯胺分解1 – 3的布朗斯台德图（log k N vs.苯胺p K a）是线性的，斜率（β）值分别为0.52、0.61和0.63。这些斜率的值和其他考虑因素表明，这些反应是由协调机制决定的。对于这些反应，k N值遵循反应序列：3 > 2 > 1。即，反应性随着与非离去基团连接的硝基的数目增加而增加。与碳酸酯的逐步pyridinolysis这项工作的反应的比较1 - 3表明两性离子四面体中间体（T ±在吡啶分解反应中形成的α）通过等位苯胺基的吡啶部分的改变而不稳定。这归因于相对于等位吡啶，苯胺的T
• Synthesis of unsymmetrical dihydro triazine-2,4-diones by the N–N bond fragmentation of urazoles followed by intramolecular cyclization
  作者：Subhaskar R. Panga、Roger G. Hall、Rashmi V. Samant、Mark Montgomery、Ashok S. Shyadligeri

  DOI：10.1016/j.tetlet.2022.154076

  日期：2022.9

  A new synthesis of unsymmetrical dihydro triazine-2,4- diones has been accomplished, through the strategy of a base-induced fragmentation of urazole derivatives, followed by an intramolecular cyclisation. Treating substituted urazole derivatives with LDA resulted in fragmentation of the N–N bond generating an imine, which was trapped in an intramolecular fashion to give products in good to excellent

  一种新的不对称二氢三嗪-2,4-二酮合成方法已通过碱诱导的乌拉唑衍生物断裂，然后进行分子内环化的策略完成。用 LDA 处理取代的 urazole 衍生物会导致 N-N 键断裂，产生亚胺，亚胺以分子内的方式被捕获，从而得到具有良好至优异产率的产品。这种转变的特点包括原子经济性和对芳基取代基的广泛耐受性。当使用不同取代的urazole衍生物时，仅获得一种二氢三嗪-2，4-二酮异构体。我们还展示了将这种二氢三嗪-2,4-二酮转化为三嗪-2,4-二酮和三嗪-2,4,6-三酮，扩大了这种方法的范围。
• Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency
  作者：George V. De Lucca、Ui Tae Kim、Brian J. Vargo、John V. Duncia、Joseph B. Santella、Daniel S. Gardner、Changsheng Zheng、Ann Liauw、Zhang Wang、George Emmett、Dean A. Wacker、Patricia K. Welch、Maryanne Covington、Nicole C. Stowell、Eric A. Wadman、Anuk M. Das、Paul Davies、Swamy Yeleswaram、Danielle M. Graden、Kimberly A. Solomon、Robert C. Newton、George L. Trainor、Carl P. Decicco、Soo. S. Ko

  DOI：10.1021/jm049530m

  日期：2005.3.1

  Starting with our previously described(20) class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase 1 clinical trials.
• Abbasi, Muhammad Athar; Sonia, Ayesha; Aziz-Ur-Rehman, Journal of the Chemical Society of Pakistan, 2013, vol. 35, # 2, p. 385 - 390
  作者：Abbasi, Muhammad Athar、Sonia, Ayesha、Aziz-Ur-Rehman、Khan, Khalid Mohammed、Ashraf, Muhammad、Afzal, Iftikhar、Ambreen, Nida、Shahid, Muhammd、Abbas, Mazhar

  DOI：——

  日期：——